Your session is about to expire
← Back to Search
mRNA-1647 for Cytomegalovirus
Study Summary
This trial will test the safety and effectiveness of a new vaccine for cytomegalovirus in healthy Japanese adults.
- Cytomegalovirus (CMV)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are adults of any age capable of participating in this experiment?
"Prospective participants must meet the specified age range of 18 to 40 years old as noted in the study's eligibility criteria."
Is participation in this trial still feasible for prospective volunteers?
"According to the information available on clinicaltrials.gov, recruitment for this research study is ongoing and was first published on November 8th 2021 with last update happening July 10th 2022."
What is the sample size of this research endeavor?
"Yes, according to clinicaltrials.gov, this medical study is still open for enrollment and has been accepting patients since November 8th 2021. As of July 10th 2022, the trial requires 28 participants from three different sites."
Has the regulatory agency sanction given its approval to mRNA-1647?
"Taking into account the limited evidence surrounding mRNA-1647's safety and efficacy, this compound was given a score of 1."
What are the eligibility criteria for participation in this research?
"This clinical trial will enrol 28 Japanese adults, aged 18-40, who are in good health and have a BMI between 18 to 35kg/m^2. Additionally, participants must meet the following criteria: CMV IgG negative/IgM negative for those seronegative or CMV IgG positive/IgM negative or IgG positive/IgM positive for those seropositive. Furthermore, they need to be born in Japan with both parents and 4 grandparents having been born there too without living outside of Japan longer than 10 years combined."
Share this study with friends
Copy Link
Messenger